The histone deacetylase inhibitor (HDAC) valproic acid downregulates MMP-2 and MMP-9 expression, reduces stem-cell-associated properties and tumor metastatic potential, and promotes the anaplastic redifferentiation of tumor cells. Here, HDAC9 is linked to neoplasm.